新型辅助化疗在乳腺癌治疗中的临床应用

目的探讨新型辅助化疗法对乳腺癌特别是晚期乳腺癌的作用和疗效。方法选取我院2006年8月-2010年9月收治的160例乳腺癌疾病患者，并按照随机分配的原则分为实验组（80例），对照组（80例），实验组采用新型辅助化疗治疗方案（TAC），对照组采用传统的化疗方法（CAF），观察指标为腋窝淋巴结和肿瘤的大小、分化变化情况。结果实验组有效例数为63例（78．75％），明显好于对照组有效例数42例（52．5％），两组的治疗效果差异有极显著性（P〈0．01）。并且实验组抗癌药物细胞毒性（依照0-IV度毒性分级）也明显低于对照组（P〈0．01），差异有极显著性。结论新型辅助化疗可以使腋窝淋巴结缩小、降低肿瘤分期、减小病灶、提高保乳手术和治性手术的成功率，值得临床推广。

Clinical effect of neoadjuvant chemotherapy on breast cancer treatment

Objective To evaluate the clinical effect of neoadjuvant chemotherapy on breast cancer .Methods 160 patients were divided into two groups ： the treatment group （80） was treated with neoadjuvant chemotherapy （TAC）, and the control group（80） was treated with traditional chemotheraphy （CAF）.The changes of axillary lymph nodes and tumor were observed during the treatment.Results The clinical efficacy in the treatment group （78.75%） was much better than that in the control group （52.5%）, and the differences between the two groups was significanct （P 〈 0.05）.Conclusion Neoadjuvant chemotherapy could decrease the size of the axillary nodes and diminish the lesion of the breast cancer, and could also decrease the tumor stage and increase the rates of successful surgery.